US Stock Market Closed

Dashboard

Repligen Corp. (RGEN)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

CEO

Tony J. Hunt

Employees

761

Industry

Scientific Products

Sector

Healthcare

Headquarters

Waltham

Exchange

NASDAQ

Summary Stats

Market Cap

8.73B

Revenue

734M

Net Income

146M

EPS

$2.52

Price-to-Earnings

63.62

Price-to-Book

4.94

Debt-to-Equity

0.35

News

Analyst Ratings

Price targets projected by 8 analysts

High

$241.00

Average

$211.50

Low

$168.00

Ratings calculated by 9 analysts

Buy

8

Hold

1

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Above by $0.20

Actual

$0.92 +27.8%

Consensus

0.72

Report Date

Year Ago

0.68

Year Ago Change %

Up 35%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites